Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...


Avalanche Biotechnologies and Annapurna Therapeutics announce proposed merger

MENLO PARK, CA and PARIS, FRANCE, February 1, 2016 – Avalanche Biotechnologies, Inc. (“Avalanche”) (Nasdaq: AAVL) and Annapurna Therapeutics SAS (“Annapurna”), a privately held biopharmaceutical company, today announced that they have entered into a definitive agreement providing for the acquisition of all outstanding shares of Annapurna by Avalanche in exchange for approximately 17.6 million newly issued shares of Avalanche common stock.

Read the entire Press Release HERE

About the Author

Jen Farmer

Jen Farmer

Executive Director


FacebookTwitterLinkedinShare on Google+
Science C.jpg


Archived in
  Scientific News



Tagged in
FARA Scientific News